ReviewFrontiers in cellular and infection microbiology2026
Virus-encoded circular RNAs in human cancer: mechanisms and clinical implications.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) are covalently closed RNA molecules generated mainly through back-splicing. Their resistance to exonuclease-mediated degradation, cell-type specificity, and regulatory versatility make them important participants in both host and viral biology. Since the initial demonstration that circular DNA tumor viruses produce abundant circRNAs, an expanding repertoire of virus-encoded circular RNAs (viro-circRNAs) has been identified in Epstein-Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), and related animal tumor viruses. Accumulating evidence indicates that viro-circRNAs are not passive transcriptional by-products; rather, they function as miRNA sponges, RNA-binding protein scaffolds, modulators of RNA stability and transcription, epigenetic or epitranscriptomic regulators, and in selected cases, templates for viral peptide or oncoprotein translation. Recent studies have refined this field by revealing noncanonical herpesvirus-driven circRNA biogenesis, EBV circRPMS1-mediated METTL3 activation and p53 interaction, hypoxia-induced EBV circLMP2A-driven angiogenesis, HPV16 circE7-mediated immune evasion through promoter histone modification, HBV-derived circRNA signaling in hepatocellular carcinoma, and HCV-derived circRNAs that support viral RNA amplification. In this review, we synthesize current evidence using a mechanistic and clinically oriented framework: first defining viro-circRNA biogenesis and validation, then summarizing virus- and cancer-specific expression patterns, followed by a detailed analysis of direct tumor-cell mechanisms, tumor microenvironment remodeling, biomarker potential, therapeutic opportunities, and unresolved challenges. This framework is intended to move the discussion beyond descriptive cataloguing and toward testable hypotheses for translational viro-circRNA research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.